DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

NCT06125834 ·Status: RECRUITING ·Phase: PHASE2

Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer

NCT03153163 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

NCT03084939 ·Status: COMPLETED ·Phase: PHASE3

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

NCT05429684 ·Status: UNKNOWN ·Phase: PHASE3

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

NCT06210776 ·Status: RECRUITING

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

NCT02947061 ·Status: UNKNOWN ·Phase: PHASE2

A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

NCT03989037 ·Status: COMPLETED ·Phase: PHASE3

Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer

NCT04900311 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer

NCT03084237 ·Status: COMPLETED ·Phase: PHASE3

The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

NCT06452706 ·Status: RECRUITING ·Phase: PHASE2

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

NCT07047365 ·Status: RECRUITING ·Phase: PHASE3

Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study

NCT05231863 ·Status: UNKNOWN

The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

NCT05263570 ·Status: RECRUITING

A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

NCT05945927 ·Status: COMPLETED

HB1801 Combined Treatment of HER2-positive Breast Cancer

NCT07116824 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies

NCT07309770 ·Status: RECRUITING ·Phase: PHASE2

A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

NCT06115902 ·Status: RECRUITING ·Phase: PHASE1

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

NCT06057610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

NCT06198751 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807 ·Status: RECRUITING ·Phase: PHASE3

A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors

NCT07130383 ·Status: RECRUITING ·Phase: PHASE2

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

NCT06126640 ·Status: RECRUITING ·Phase: PHASE3

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

NCT05838066 ·Status: RECRUITING ·Phase: PHASE3

Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

NCT06375707 ·Status: RECRUITING ·Phase: PHASE2

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

NCT06383767 ·Status: RECRUITING ·Phase: PHASE3